Clin2
NCT06706232Possibly a fitRecruiting

Psilocybin for Depression and Suicidal Thoughts in Bipolar II

Bipolar II DisorderDepression, BipolarSuicidality

Treatments studied

Part of Mental health clinical trials.

This trial tests if two doses of psilocybin, given under medical supervision, are safe and acceptable for people with Bipolar II disorder who have mild to moderate depression and certain suicidal thoughts. The goal is to see if it may help improve mood and reduce suicidal thinking.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
10 people
Ages
25 years to 70 years
Study type
Interventional

Who can take part

  • You are 25 to 69 years old.
  • You have been diagnosed with Bipolar II disorder (a type of bipolar where you have depression and less severe highs).
  • You currently have mild to moderate depression and some suicidal thoughts (like feeling you are a burden or don't belong).
  • You are willing to slowly stop certain medications (like antidepressants, mood stabilizers, or cannabis) for the study period, starting 5 weeks before the psilocybin doses, and be off them for at least 2 weeks before each dose.
  • You pass a medical checkup (physical exam, heart test, blood draw, urine test, and psychiatric evaluation).
  • You can attend all study visits and complete questionnaires without help.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06943573Not yet recruiting· Phase 3
Psilocybin therapy for bipolar II depression

This trial tests whether psilocybin (a substance found in certain mushrooms) given with therapy can help people with bipolar II disorder who are currently in a major depression that hasn't responded to other treatments. You'll receive the drug in a supportive setting, and researchers will follow your progress to see if it's safe and effective.

Vancouver, British Columbia
NCT07281352Recruiting· Phase 1/Phase 2
Psilocybin therapy for depression

This study tests if psilocybin (a psychedelic) combined with cognitive behavioral therapy (CBT) can help people with major depression. You would receive the psilocybin in a supervised setting and have talk therapy before and after.

Los Angeles, California
NCT06247839Recruiting· Phase 3
Psilocybin for depression: changing self-focus

This trial tests whether a single dose of psilocybin can help people with treatment-resistant depression by changing how they focus on themselves. It aims to understand how psilocybin affects brain activity and self-related thinking.

Charlestown, Massachusetts
NCT06072898Recruiting· Phase 2
Psilocybin brain imaging trial for depression

This study tests whether a single dose of psilocybin (a psychedelic compound) can help treat depression by looking at brain changes on MRI. It is designed for people with moderate-to-severe depression who have not responded well to other treatments.

Toronto, Ontario
NCT06378229Recruiting· Phase 2
Psilocybin for hospitalized treatment-resistant depression

This trial tests whether a single dose of psilocybin can help hospitalized patients with tough-to-treat depression. It focuses on people who haven't improved with standard antidepressants and need a new option.

Ghent, Oost-Vlaanderen
NCT06442423Recruiting· Phase 1
Psilocybin study for people with psychiatric symptoms

This trial tests if psilocybin, a substance found in certain mushrooms, can help people with various mental health symptoms that affect daily life. You would take a single dose in a supervised setting and be monitored for changes in your mood and well-being.

New Haven, Connecticut

Hear when a new Bipolar II Disorder trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.